Elanco Reports 10% Revenue Growth to $1.368 Billion in Q2 2026

Elanco Animal Health Incorporated reported a significant increase in financial performance for the second quarter of 2026, with total revenue reaching $1.368 billion, a 10% increase from $1.241 billion in the same period of 2025. For the first half of 2026, revenue totaled $2.739 billion, up 13% from $2.434 billion year-over-year. The company's net income also saw a substantial rise, reaching $54 million for the quarter, compared to $11 million in Q2 2025, and $111 million for the first half of 2026, up from $78 million in the prior year. This growth in profitability was reflected in earnings per share, which increased to $0.11 for the quarter and $0.22 for the six months ended June 30, 2026.

The increase in revenue was driven by strong performance in both the pet health and farm animal segments. Pet health revenue rose by 12% to $718 million in Q2 2026, supported by new product launches such as Zenrelia and Credelio Quattro. Farm animal revenue also increased by 9% to $633 million, primarily due to growth in ruminants and poultry, despite a decline in swine volumes. The company attributed the overall revenue growth to higher volumes, increased pricing, and favorable foreign currency exchange rates, with approximately 52% of revenue generated in currencies other than the U.S. dollar.

Strategically, Elanco completed the acquisition of AHV International B.V. on April 30, 2026, for an estimated total consideration of $243 million. This acquisition is expected to enhance Elanco's product portfolio in the farm animal sector, particularly in Europe and the U.S., and is anticipated to contribute modestly to revenue in 2026, with a more significant impact expected in 2027. The company also reported ongoing restructuring efforts aimed at optimizing its global footprint and investing in innovation, which are projected to yield savings of approximately $25 million in 2026 and $60 million in 2027.

Operationally, Elanco's total assets increased to $13.561 billion as of June 30, 2026, up from $13.358 billion at the end of 2025. The company reported a total employee headcount of approximately 7,000, reflecting a reduction of about 300 employees due to restructuring initiatives. The company also noted that it remains in compliance with all debt covenants, with cash and cash equivalents of $530 million and unused borrowing capacity of approximately $750 million under its revolving credit facility.

Looking ahead, Elanco anticipates continued revenue growth driven by its product pipeline and strategic initiatives. The company is focused on integrating the AHV acquisition and leveraging its expanded product offerings to enhance market share. However, Elanco remains cautious of potential macroeconomic challenges, including fluctuations in foreign currency exchange rates and changes in trade policies, which could impact future performance.